1. Homepage
  2. Equities
  3. Bangladesh
  4. Dhaka Stock Exchange
  5. Beximco Pharmaceuticals Limited
  6. News
  7. Summary
    BXPHARMA   BD0453BXPH04

BEXIMCO PHARMACEUTICALS LIMITED

(BXPHARMA)
  Report
End-of-day quote Dhaka Stock Exchange  -  05-18
150.20 BDT   -0.53%
04/28Beximco Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022
CI
04/01Beximco Pharmaceuticals Renames Sanofi Bangladesh Subsidiary To Synovia Pharma
MT
03/17Beximco Lands Sub-License From United Nations-Backed Program For COVID-19 Treatment
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Beximco Pharmaceuticals Limited Launches First Generic Version of Pfizer's COVID-19 Treatment Paxlovid

12/30/2021 | 05:38am EDT

Beximco Pharmaceuticals Limited announces the launch of the world's first generic version of Pfizer's COVID-19 treatment Paxlovid (nirmatrelvir and ritonavir tablets, co-packaged for oral use) which was granted emergency use authorization (EUA) by the US FDA on 22 December 2021. Directorate General of Drug Administration (DGDA), Bangladesh, has granted EUA for the oral antiviral drug to treat mild-to-moderate COVID-19 in adults and children of 12 years and above. This novel antiviral pill showed almost 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and recent data from Pfizer suggests the drug retains its effectiveness against the fast-spreading Omicron variant of the coronavirus. Beximco Pharma will market this product under the brand name Bexovid, initially in Bangladesh. Nirmatrelvir inhibits a SARS-CoV-2 enzyme to stop the virus from replicating, and ritonavir slows down nirmatrelvir's breakdown to help it remain in the body for a longer period at higher concentrations. The treatment is given as two tablets of nirmatrelvir and one tablet of ritonavir together twice a day for five days. Bexovid is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset.


© S&P Capital IQ 2021
All news about BEXIMCO PHARMACEUTICALS LIMITED
04/28Beximco Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine..
CI
04/01Beximco Pharmaceuticals Renames Sanofi Bangladesh Subsidiary To Synovia Pharma
MT
03/17Beximco Lands Sub-License From United Nations-Backed Program For COVID-19 Treatment
MT
03/17United Nations-Backed Medicines Patent Pool Grants Beximco Pharmaceuticals Limited's Su..
CI
01/28Earnings Flash (BXP.L) BEXIMCO PHARMACEUTICALS Posts Fiscal H1 Revenue $17M
MT
01/28Earnings Flash (BXP.L) BEXIMCO PHARMACEUTICALS Posts Fiscal H1 EPS $7.12
MT
01/28Beximco Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six..
CI
01/20Beximco Jumps 6% on License to Produce Merck & Co.'s COVID-19 Drug in Bangladesh
MT
01/20Dozens of firms to make cheap version of Merck COVID pill for poorer nations
RE
01/20Beximco Pharmaceuticals Limited Granted License to Produce Molnupiravir for Covid-19
CI
More news
Financials
Sales 2022 34 856 M 411 M 411 M
Net income 2022 6 242 M 73,5 M 73,5 M
Net Debt 2022 9 750 M 115 M 115 M
P/E ratio 2022 9,95x
Yield 2022 2,93%
Capitalization 67 006 M 789 M 789 M
EV / Sales 2022 2,20x
EV / Sales 2023 1,87x
Nbr of Employees 5 500
Free-Float 94,3%
Chart BEXIMCO PHARMACEUTICALS LIMITED
Duration : Period :
Beximco Pharmaceuticals Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Last Close Price 150,20 BDT
Average target price 182,00 BDT
Spread / Average Target 21,2%
EPS Revisions
Managers and Directors
Nazmul Hassan Chief Executive Officer, Director & MD
Mohammad Ali Nawaz Chief Financial Officer
Ahmed Sohail Fasihur Rahman Chairman
Selina Akter Executive Director-Medical Affairs Department
Rabbur Reza Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BEXIMCO PHARMACEUTICALS LIMITED-22.06%789
JOHNSON & JOHNSON1.68%465 705
PFIZER, INC.-11.14%294 404
ELI LILLY AND COMPANY8.19%269 013
ABBVIE INC.11.53%266 851
ROCHE HOLDING AG-15.67%266 707